The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1752
ISSUE 1752
April 13, 2026
Issue 1752
- Pivmecillinam (Pivya) for Uncomplicated UTI
- Etripamil Nasal Spray (Cardamyst) for Paroxysmal Supraventricular Tachycardia
- Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome
- In Brief: A Bumetanide Nasal Spray (Enbumyst) for Edema
- In Brief: Ranitidine Returns
- In Brief: Rybelsus R2 Rebranded as Ozempic
- In Brief: Optune Pax — A Portable Device for Pancreatic Cancer (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Pivmecillinam (Pivya) for Uncomplicated UTI
April 13, 2026 (Issue: 1752)
The FDA has approved pivmecillinam (Pivya – Utility
Therapeutics), an oral penicillin-class antibacterial
drug, for treatment of uncomplicated urinary tract
infections (uUTIs) caused by susceptible isolates of
Escherichia coli, Proteus...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
